Mast cells, angiogenesis and cancer

Advances in Experimental Medicine and Biology

Volumn 716, Issue , 2011, Pages 270-288

  Ribatti, Domenico ^a   Crivellato, Enrico ^b  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; IMATINIB; SILYMARIN;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL FUNCTION; CELL HOMING; DISEASE ASSOCIATION; DRUG MECHANISM; EXPERIMENTAL MODEL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; LIVER CANCER; LYMPHANGIOGENESIS; MALIGNANT NEOPLASTIC DISEASE; MAST CELL; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; TUMOR VASCULARIZATION; ANIMAL; CYTOLOGY; IMMUNOLOGY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); REVIEW; VASCULARIZATION;

ANIMALS; HUMANS; MAST CELLS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 79960896329     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-9533-9_14     Document Type: Article

References (144)

1. Ehrlich P. Beitrage zur Theorie und Praxis der histologischen Farbung. 1878, Thesis, Leipzig University.
2. Crivellato E, Beltrami C, Mallardi F et al. Paul Ehrlich's doctoral thesis: a milestone in the study of mast cells. Br J Haematol 2003a; 123:19-21. (Pubitemid 37222753)
3. Galli SJ, Kalesnikoff J, Grimbaldeston M.A et al. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005a; 23:749-86. (Pubitemid 40563184)
4. Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol 2005b; 6:135-42. (Pubitemid 40268194)
5. Coussens LM, Raymond WW, Bergers G et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999; 13:1382-97. (Pubitemid 29270244)
6. Gounaris E, Erdman SE, Restaino C et al. Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci USA 2007; 104:19977-82.
7. Soucek L, Lawlor ER, Soto D et al. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 2007; 13:1211-8. (Pubitemid 47530639)
8. Nakayama T, Yao L, Tosato G. Mast cell-derived angiopoietin-1 plays a role in the growth of plasma cell tumors. J Clin Invest 2004; 114:1317-25. (Pubitemid 40385303)
9. Hart P, Townley S, Grimbaldeston M et al. Mast cells, neuropeptides, histamine and prostaglandins in UV-induced systemic immunosuppression. Methods 2002; 28:79-89.
10. Church M, Levi-Schaffer F. The human mast cell. J Allergy Clin Immunol 1997; 99:155-160. (Pubitemid 27091561)
11. Hart P, Grimbaldeston M, Finlay-Jones J. Immunosuppression and skin cancer: role of histamine and mast cells. Clin Exp Pharmacol Physiol 2001; 28:1-8. (Pubitemid 32039550)
12. Okayama Y, Kawakami T. Development, migration and survival of mast cells. Immunol Res 2006; 34:97-115. (Pubitemid 43997964)
13. Metz M, Grimbaldeston MA, Nakae S et al. Mastcells in the promotion and limitation of chronic inflammation. Immunol Rev 2007; 217:304-28. (Pubitemid 46718153)
14. Huang B, Lei Z, Zhang GM et al. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 2008; 112:1269-79.
15. Nowak EC, Weaver CT, Turner H et al. IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med 2009; 206:1653-60.
16. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004; 4:937-47. (Pubitemid 39626217)
17. Ditsworth D, Zong WX. NF-kappaB: key mediator of inflammation-associated cancer. Cancer Biol Ther 2004; 3:1214-6. (Pubitemid 41350955)
18. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003; 21:807-39. (Pubitemid 37174548)
19. Munn DH, Mellor AL. The tumor-draining lymph node as an immune-privileged site. Immunol Rev 2006; 213:146-58. (Pubitemid 44401499)
20. Ullrich SE, Nghiem DX, Khaskina P. Suppression of an established immune response by UVA-a critical role for mast cells. Photochem Photobiol 2007; 83:1095-100. (Pubitemid 47438536)
21. Grimbaldenston MA, Nakae S, Kalesnikoff K et al. Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat Immunol 2007; 38:1095-104. (Pubitemid 47423757)
22. Lu LF, Lind EF, Gondek DC et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006; 442:997-1002. (Pubitemid 44330250)
23. Kripke M. Immunological unresponsiveness induced by ultraviolet radiation. Immunol Rev 1984; 80:87-102. (Pubitemid 14060750)
24. Ch'ng S, Wallis RA, Yuan L. Mast cells and cutaneous malignancies. Modern Pathol 2006; 19:149-59. (Pubitemid 43250990)
25. Wille J, Kydonieus A, Murphy G. Cis-urocanic acid induces mast cell degranulation and release of preformed TNF-alpha: a possible mechanism linking UVB and cis-urocanic acid to immunosuppression of contact hypersensitivity. Skin Pharmacol Physiol 1999; 12:18-27. (Pubitemid 29257447)
26. Chen W, Jin W, Hardegen N et al. Conversion of peripheral CD4*CD25∼ naive T-cells to CD4*CD25( regulatory T-cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198:1875-86. (Pubitemid 38032120)
27. Kambayashi T, Allenspach EJ, Chang JT et al. Inducible MHC class II expression by mast cells supports effector and regulatory T-cell activation. J Immunol 2009; 182:4686-95.
28. Ju MJ, Qiu SJ, Gao Q et al. Combination of peritumoral mast cells and T-regulatory cells predicts prognosis of hepatocellular carcinoma. Cancer Sci 2009; 100:1267-74.
29. Conti P, Pang X, Boucher W et al. Impact of Rantes and MCP-1 chemokines on in vivo basohilic mast cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase. Blood 1997; 89:4120-7. (Pubitemid 27220960)
30. Theoharides T, Conti P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 2004; 25:235-41. (Pubitemid 38501669)
31. Dabbous M, Walker R, Haney L et al. Mast cells and matrix degradation at sites of tumor invasion in rat mammary adenocarcinoma. Br J Cancer 1986; 54:459-65. (Pubitemid 16031549)
32. Stack MS, Johnson DA. Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). J Biol Chem 1994; 269:9416-9. (Pubitemid 24196529)
33. Baram D, Vaday G, Salamon P et al. Human mast cells release metalloproteinase-9 on contact with activated T-cells: juxtacrine regulation by TNF-alpha. J Immunol 2001; 167:4009-16.
34. Hara M, Matsumori A, Ono K et al. Mast cells cause apotosis of cardiomyocytes and proliferation of other intramyocardial cells in vitro. Circulation 1999; 100:1443-9. (Pubitemid 29451706)
35. He S, a Walls AF. Human mast cell chymase induces the accumulation of neutrophils, eosinophils and other inflammatory cells in vivo. Br J Pharmacol 1988; 125:1491-1500.
36. Sakamoto S, Goldhaber P, Glimcher M. The effect of heparin on the amount of enzyme released in tissue culture and on the activity of the enzyme. Calcif Tissue Int 1973; 12:247-58.
37. Markwardt F, Klocking H. Heparin-induced release of plasminogen activator. Haemostasis 1977; 6:370-4. (Pubitemid 8276144)
38. Niwa Y, Kasugai T, Ohno K et al. Anemia and mast cells depletion in mutant rats that are homozygous at 'white spotting (Ws)' locus. Blood 1991; 78:1936-41.
39. Lazar-Molnar E, Hegyesi H, Pallinger E et al. Inhibition of human primary melanoma cell proliferation by histamine is enhanced by interleukin-6. Eur J Clin Invest 2002; 32:743-9. (Pubitemid 35334969)
40. Burtin C, Ponvert C, Fray A. Inverse correlation between tumor incidence and tissue histamine levels in W/Wv, W/+ and +/+ mice. J Natl Cancer Inst 1985; 74:671-4. (Pubitemid 15099243)
41. Halaban R, Kwon BS, Ghosh S et al. bFGF as an autocrine growth fator for human melanomas. Oncogene Res 1988; 3:177-86. (Pubitemid 19085035)
42. Schadendorf D, Moller A, Algermissen B et al. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol 1993; 151:2667.
43. Mukheriee S, Bandyopadhyay G, Dutta C et al. Evaluation of endoscopic biopsy in gastric lesions with a special reference to the significance of mast cell density. Indian J Pathol Microbiol 2009; 52:20-4.
44. Imai T, Michizawa M, Shimizu H et al. Bilateral multiple spindle cell lipomas of the tongue. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 106:264-9.
45. Nakashima K, Yamada N, Yoshida Y et al. Solitary sclerotic neurofibroma of the skin. Am J Dermatopathol 2008; 30:278-280.
46. Leon A, Ceauju Z, Ceauju M et al. Mast cells and dendritic cells in basal cell carcinoma. Rom J Morphol Embryol 2009; 50:85-90.
47. Aoki M, Pawankar R, Niimi Y et al. Mast cells in basal cell carcinoma express VEGF, IL-8 and RANTES. Int Arch Allergy Immunol 2003; 130:216-23. (Pubitemid 36359525)
48. Oliveira CR, Albuquerque GC, Simon EF et al. Case for diagnosis. Telangectasia macularis eruptive perstans. An Bras Dermatol 2009; 84:87-9.
49. Kilif A, Kosem M, Demirok A et al. Conjunctival myxoma: a clinicopathologic report. Ophthalmic Surg Lasers Imaging 2008; 39:514-6.
50. Srinvasan R, Gautman U, Gupta R et al. Synovial sarcoma: diagnisos on fine-needle aspiration by morphology and molecular analysis. Cancer Cytopathol 2009; 117:128-36.
51. Ribatti D, Ennas MG, Vacca A et al. Tumor vascularity and tryptase positive-mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest 2003b; 33:420-5. (Pubitemid 36583711)
52. Iamaroon A, Pongsirlwet S, Jittidecharaks S et al. Increase of mast cells and tumor angiogenesis in oral squamous cell carcinoma. J Oral Pathol Med 2003; 32:195-9. (Pubitemid 36604013)
53. Rojas IG, Spencer ML, Martinez A et al. Characterization of mast cell subpopulations in lip cancer. J Oral Pathol Med 2005; 34:268-73. (Pubitemid 40524966)
54. Sharma VK, Agrawal AK, Pratarp VK et al. Mast cell reactivity in lymphoma: a preliminary communication. India J Cancer 1992; 29:61-5. (Pubitemid 23156158)
55. Molin D, Edstrom A, Glimelius I et al. Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Haematol 2002; 119:122-4. (Pubitemid 35176509)
56. Molin D. Bystander cells and prognosis in Hodgkin lymphoma. Review based on a doctoral thesis. Ups J Med Sci 2004; 109:179-228. (Pubitemid 39345454)
57. Fukushima H, Ohsawa M, Ikura Y et al. Mast cells in diffuse large B-cell lymphoma; their role in fibrosis. Histopathology 2006; 49:498-505. (Pubitemid 44631623)
58. Fukushima N, Satoh T, Sano M et al. Angiogenesis and mast cells in nonHodgkin's lymphoma: strong correlation in angioimmunoblastic T-cell lymphoma. Leuk Lymphoma 2001; 42:709-20. (Pubitemid 32782779)
59. Dave SS, Wright G, Than B et al. Prediction of survival in follicular lymphoma based on molecular features oftumor-infilitrating immune cells. N Engl J Med 2004; 351:2159-69. (Pubitemid 39507628)
60. Nechushtan H, Razin E. The function of MIFT and associated proteins in mast cells. Mol Immunol 2002; 38:1177-80. (Pubitemid 35253750)
61. Tournilhac O, Santos DD, Xu L et al. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol 2006; 17:1275-82. (Pubitemid 44288218)
62. Nonomura N, Takayama H, Nishimura K et al. Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer. Br J Cancer 2007; 97:952-6. (Pubitemid 47519307)
63. Fleiscmann A, Schlomm T, Kollermann J et al. Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis. Prostate 2009; 69:976-81.
64. Gomes AP, Johann JE, Lovato GG et al. Comparative analysis of the mast cell density in normal oral mucosa, actinic cheilitis and lip squamous cell carcinoma. Braz Dent J 2008; 19:186-9.
65. Lago Costa N, Ferreira Oton-Lelte A, Pelxodo Chelm-Junlor A et al. Density and migration of mast cells in lip squamous cell carcinoma and actinic cheilitis. Histol Histopathol 2009; 24:457-65.
66. Rojas IG, Martinez A, Brethauer U et al. Actinic cheilitis: epithelial expression of COX-2 and its association with mast cell tryptase and PAR-2. Oral Oncol 2009; 45:284-90.
67. Oliveira-Neto HH, Ferreira Leite A, Lago Costa N et al. Decrease in mast cells in oral squamous cell carcinoma: Possible failure in the migration of these cells. Oral Oncol 2007; 43:484-90. (Pubitemid 46561433)
68. Aaltomaa S, Lipponen P, Papinaho S et al. Mast cells in breast cancer. Anticancer Res 1993; 13:785-8. (Pubitemid 23216984)
69. Dabiri S, Huntsman D, Makretsov N et al. The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. Mod Pathol 2004; 17:690-5. (Pubitemid 38715492)
70. Gooch SJ, Lee AV, Yee D. Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res 1998; 58:4199-205. (Pubitemid 28440580)
71. Ohno S, Inagawa H, Soma G et al. Role of tumor-associated macrophage in malignant tumors: should the location of the infiltrated macrophages be taken into account during evaluation? Anticancer Res 2002; 22:4269-75. (Pubitemid 36134471)
72. Samoszuk M, Corwin MA. Mast cell inhibitor cromolyn increases blood clotting and hypoxia in murine breast cancer. Int J Cancer 2003; 107:159-63. (Pubitemid 37100102)
73. Kankkunen JP, Harvima IT, Naukkarinen A. Qunatitative analysis of tryptase and chymase containing mast cells in benign and malignant breast lesions. Int J Cancer 1997; 72:385-8. (Pubitemid 27325861)
74. Thorense S, Tangen M, Hartveit F. Mast cells in the axillary nodes of breast cancer patients. Diagn Histopathol 1982; 5:65-7. (Pubitemid 12182270)
75. Della Rovere F, Granata A, Monaco M et al. Phagocytosis of cancer cells by mast cells in breasr cancer. Anticancer Res 2009; 29:3157-61.
76. Amini RM, Aaltonen K, Nevanlinna H et al. Mast cells and eosinophils in invasive breast carcinoma. BMC Cancer 2007; 7:165-9.
77. Welsh TJ, Green RH, Richardson D et al. Macrophage and mast cell invasion of tumor cell islets confers a marked survival advantage in non small-cell lung cancer. J Clin Oncol 2005; 23:8959-67. (Pubitemid 46211481)
78. Chan JK, Magistris A, Loizzi V et al. Mast cell density, angiogenesis, blood clotting and prognosis in women with advanced ovarian cancer. Gynecol Oncol 2005; 99:20-5. (Pubitemid 41354578)
79. Cinel L, Aban M, Bastruk M et al. The association of mast cell density with myometrial invasion in endometrial carcinoma: a preliminary report. Pathol Res Pract 2009; 205:255-8.
80. All G, Boldrini L, Lucchi M et al. Tryptase mast cells in malignant pleural mesothelioma as an independent favorable prognostic factor. J Thorac Oncol 2009; 4:348-54.
81. Thorton SC, Mueller SM, Levine EM. Human endothelial cells: use of heparin in cloning and long term cultivation. Science 1983; 222:623-5. (Pubitemid 13022412)
82. Alessandri G, Raju KS, Gullino PM. Characterization of a chemoattractant for endothelium induced by angiogenic effectors. Cancer Res 1984; 44:1579-84. (Pubitemid 14125848)
83. Ribatti D, Roncali L, Nico B et al. Effects of exogenous heparin on the vasculogenesis ofthe chorioallantoic membrane. Acta Anat 1987; 130:257-63.
84. Norrby K, Sorbo J. Heparin enhances angiogenesis by a systemic mode of action. Int J Exp Pathol 1992; 73:1451-5.
85. Norrby K. Heparin and angiogenesis: a low molecular weight fraction inhibits and a high molecular weight fraction stimulates angiogenesis systematically. Haemostasis 1993; 23:144-9.
86. Jakobson AM, Hahnenberger R. Antiangiogenic effect of heparin and other sulphated glycosaminoglycans in the chick embryo chorioallantoic membrane. Pharmacol Toxicol 1991; 69:122-6.
87. Wilks JW, Scott PS, Urla LK et al. Inhibition of angiogenesis with combination treatments of angiostatic steroids and suramin. Int J Radiat Biol 1991; 60:73-7.
88. Castellot JJ, Karnovsky MJ, Spiegelman BM. Differentiation-dependent stimulation of neovascularization and endothelial cell chemotaxis by 3T3 adipocytes. Proc Natl Acad Sci USA 1982; 79:5597-5601. (Pubitemid 13197691)
89. Taylor S, Folkman J. Protamine is an inhibitor of angiogenesis. Nature 1982; 297:307-12. (Pubitemid 12025053)
90. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267:10931-4.
91. Yayou A, Klagsbrun M, Esko JD et al. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991; 64:841-8. (Pubitemid 121001170)
92. Sorbo J, Jakobsson A, Norrby K. Mast-cell histamine is angiogenic through receptors for histamine1 and histamine2. Int J Exp Pathol 1994; 75:43-50. (Pubitemid 24197569)
93. Thompson WD, Campbell R, Evans T. Fibrin degradation and angiogenesis: quantitative analysis of the angiogenic response in the chick chorioallantoic membrane. J Pathol 1995; 145:27-37.
94. Fang KC, Wolters PJ, Steinhoff M et al. Mast cell expression of gelatinase A and B is regulated by kit ligand and TGF-p. J Immunol 1999; 162:5528-35. (Pubitemid 29307165)
95. Di Girolamo N, Wakefiled D. In vitro and in vivo expression of interstitial collagenase/MMP-1 by human mast cells. Dev Immunol 2000; 7:131-42.
96. Vincent AJ, Zhang J, Ostor A et al. Matrix metalloproteinase-1 and-3 and mast cells are present in the endometrium of women using progestin-only contraceptives. Human Reprod 2000; 15:123-30. (Pubitemid 30035111)
97. Raza SL, Cornelius LA. Matrix metalloproteinases: pro- and anti-angiogenic activities. J Invest Dermatol Symp Proc 2000; 5:47-54.
98. Taiplae J, Lohi J, Saarinen J et al. Human mast cell chymase and leukocyte elestase release latent transforming growth factor beta-1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Biol Chem 1995; 270:4689-96.
99. Gruber BL, Marchese MJ, Suzuki K et al. Synovial procollagenase activation by human mast cell tryptase dependence upon matrix metalloproteinase 3 activation. J Clin Invest 1989; 84:1657-62. (Pubitemid 19272256)
100. Blair RJ, Meng H, Marchese MJ et al. Tryptase is a novel, potent angiogenic factor. J Clin Invest 1997; 99:2691-2700.
101. Muramatsu M, Katada J, Hattori M et al. Chymase mediates mast cell-induced angiogenesis in the hamster sponge granuloma. Eur J Pharmacol 2000a; 402:181-91. (Pubitemid 30625325)
102. Muramatsu M, Katada J, Hattori M et al. Chymase as a proangiogenic factor; a possible involvement of chymase-angiotensin-dependent pathway in the hamster sponge angiogenesis model. J Biol Chem 2000b; 275:5545-52. (Pubitemid 30115190)
103. Qu Z, Kayton RJ, Ahmadi P et al. Ultrastructural immunolocalization of basic fibroblast growth factor in mast cell secretory granules: morphological evidence for bFGF release through degranulation. J Histochem Cytochem 1998; 46:1119-28. (Pubitemid 28445286)
104. Grutzkau A, Kruger-Krasagakes S, Baumeister H et al. Synthesis, storage and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF 206. Mol Biol Cell 1998; 9:875-84. (Pubitemid 28173640)
105. Cantarella G, Lempereur L, Presta M et al. Nerve growth factor-endothelial cell interactions lead to angiogenesis in vitro and in vivo. FASEB J 2002; 16:1307-1309.
106. Emanueli C, Salis MB, Pinna A et al. Nerve growth factor promotes angiogenesis and arteriogenesis in ischemic hindlimbs. Circulation 2002; 106:2257-62. (Pubitemid 35222222)
107. Kessler DA, Langer RS, Pless NA et al. Mast cells and tumor angiogenesis. Int J Cancer 1976; 18:703-9.
108. Poole TJ, Zetter BR. Stimulation of rat peritoneal mast cell migration by tumor-derived peptides. Cancer Res 1983; 43:5857-61. (Pubitemid 14212652)
109. Starkey JR, Crowle PK, Taubenberger S. Mast cell-deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis. Int J Cancer 1988; 42:48-52.
110. Ribatti D, Crivellato E, Candussio L et al. Mast cells and their secretory granules are angiogenic in the chick embryo chorioallantoic membrane. Clin Exp Allergy 2001; 31:602-8. (Pubitemid 34204285)
111. Benitez-Bribiesca L, Wong A, Utrera D et al. The role of mast cell tryptase in neoangiogenesis of premalignant and malignant lesions of the uterine cervix. J Histochem Cytochem 2001; 49:1061-2. (Pubitemid 32675015)
112. Ribatti D, Finato N, Crivellato E et al. Neovascularization and mast cells with tryptase activity increase simultaneously with pathologic progression in human endometrial cancer. Am J Obstet Gynecol 2005; 193:1961-5. (Pubitemid 41737619)
113. Sawatsubashi M, Yamada T, Fukushima N et al. Association of vascular endothelial growth factor and mast cells with angiogenesis in laryngeal squamous cell carcinoma. Virchows Arch 2000; 436:243-8. (Pubitemid 30168683)
114. Imada D, Shijubo N, Kojima H et al. Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur Resp J 2000; 15:1087-93. (Pubitemid 30399279)
115. Takanami I, Takeuchi K, Narume M. Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 2000; 88:2686-92. (Pubitemid 30417928)
116. Tomita M, Matsuzaki Y, Onitsuka T. Effect of mast cell on tumor angiogenesis in lung cancer. Ann Thorac Surg 2000; 69:1686-90. (Pubitemid 30445506)
117. Toth T, Toth-Jakatics R, Jimi S et al. Cutaneous malignant melanoma: correlation between neovascularization and peritumor accumulation of mast cells overexpressing vascular endothelial growth factor. Hum Pathol 2000; 31:955-60.
118. Ribatti D, Vacca A, Ria R et al. Neovascularization, expression of fibroblast growth factor-2 and mast cell with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. Eur J Cancer 2003; 39:666-75.
119. Elpek GO, Gelen T, Aksoy NH et al. The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the oesophagus. J Clin Pathol 2001; 54:940-4. (Pubitemid 34032889)
120. Guidolin D, Crivellato E, Nico B et al. An image analysis of the spatial distribution of perivascular mast cells in human melanoma. Int J Mol Med 2006; 17:981-7.
121. Ng L, Beer TW, Murray K. Vascular density has prognostic value in Merkel cell carcinoma. Am J Dermatopathol 2008; 30:442-5.
122. Yodavudh S, Tangjitgamol S, Puangsa-art S. Prognostic significance of microvessel density and mast cell density for the survival of Thai patients with primary colorectal cancer. J Med Assoc Thai 2008; 91:723-32. (Pubitemid 351776226)
123. Gulubova M, Vlaykova T. Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer. J Gastroenterol Hepatol 2009; 24:1265-75.
124. Ribatti D, Finato N, Crivellato E et al. Angiogenesis and mast cells in human breast cancer sentinel lymph nodes with and without micrometastases. Histopathology 2007; 51:837-42. (Pubitemid 350179407)
125. Ranieri G, Ammendola M, Patruno R et al. Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol 2009; 35:115-20.
126. Ribatti D, Nico B, Vacca A et al. Do mast cells help to induce angiogenesis in B-cell nonHodgkin's lymphomas? Br J Cancer 1998; 77:1900-6. (Pubitemid 28254631)
127. Ribatti D, Vacca A, Marzullo A et al. Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell nonHodgkin's lymphomas. Int J Cancer 2000; 82:171-5. (Pubitemid 30023063)
128. Glimelius I, Edstrom A, Fischer M et al. Angiogenesis and mast cells in Hodgkin's lymphoma. Leukemia 2005; 19:2360-2. (Pubitemid 41741642)
129. Terpos E, Tasidou A, Kastritis E et al. Angiogenesis in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009; 9:46-9.
130. Ribatti D, Vacca A, Nico B et al. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer 1999; 79:451-5. (Pubitemid 29046218)
131. Crivellato E, Nico B, Vacca A et al. Mast cell heterogeneity in B-cell nonHodgkin's lymphomas: an ultrastructural study. Leuk Lymphoma 2002; 43:2201-5. (Pubitemid 35174734)
132. Crivellato E, Nico B, Vacca A et al. Ultrastructural analysis of mast cell recovery after secretion by piecemeal degranulation in B-cell nonHodgkin's lymphoma. Leuk Lymphoma 2003; 44:517-21. (Pubitemid 36113898)
133. Kops SK, Van Loveren H, Rosenstein RW et al. Mast cell activation and vascular alterations in immediate hypersensitivity-like reactions induced by a T-cell derived antigen-binding factor. Lab Invest 1984; 50:421-34. (Pubitemid 14136707)
134. Theoharides T, Kempuraj D, Tagen M et al. Differential release of mast cells mediators and the pathogenesis of inflammation. Immunol Rev 2007; 217:65-78. (Pubitemid 46718152)
135. Ribatti D, Polimeno G, Vacca A et al. Correlation of bone marrow angiogenesis and mast cells with tryptase activity in myelodysplastic syndromes. Leukemia 2002; 16:1680-4.
136. Molica S, Vacca A, Crivellato E et al. Tryptase-positive mast cells predict clinical outcome of patients with early B-cell chronic lymphocytic leukemia. Eur J Haematol 2003; 71:137-9. (Pubitemid 36951650)
137. Ribatti D, Molica S, Vacca A et al. Tryptase-positive mast cells correlate positively with bone marrow angiogenesis in B-cell chronic lymphocytic leukemia. Leukemia 2003; 17:1428-30. (Pubitemid 36857360)
138. Heinrich MC, Griffith DJ, Druker BJ et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571 a selective tyrosine kinase inhibitor. Blood 2000; 96:925-32. (Pubitemid 30618049)
139. Kitamura Y, Hirotab S. Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci 2004; 61:2924-31. (Pubitemid 40104590)
140. Akin C, Metcalfe DD. The biology of Kit in disease and the application of pharmacogenetics. J Allergy Cin Immunol 2004; 114:13-9. (Pubitemid 39005112)
141. Nielsen HJ, Christenseb IJ, Svendsen MN et al. Ranitidine as adjuvant treatment in colorectal cancer. Br J Surg 2002; 89:1416-22.
142. Parshad R, Kapoor S, Gupta SD. Does famotidine enhance tumor infiltrating lymphocytes in breast cancer? Results of a randomized prospective pilot study. Acta Oncol 2002; 41:362-5.
143. Molica S, Montillo M, Ribatti D et al. Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab- consolidation therapy in advanced chronic lymphocytic leukemia. Haematologica 2007; 92:1367-74. (Pubitemid 350144154)
144. Ramakrishnan G, Jagan S, Kamaraj S et al. Silymarin attenuated mast cell recruitment thereby decreased the expressions of matrix metalloproteinases-2 and 9 in rat liver carcinogenesis. Invest New Drugs 2009; 27:233-40.